Your browser doesn't support javascript.
loading
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi, Kazuo; Toyoda, Masao; Hatori, Nobuo; Sakai, Hiroyuki; Furuki, Takayuki; Sato, Kazuyoshi; Terauchi, Yasuo; Tamura, Kouichi; Kanamori, Akira.
Afiliação
  • Kobayashi K; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1 Fujimicho naka-ku, Yokohama City, Kanagawa Prefecture, Japan. k-taishi@xc4.so-net.ne.jp.
  • Toyoda M; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. k-taishi@xc4.so-net.ne.jp.
  • Hatori N; Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara, Japan.
  • Sakai H; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1 Fujimicho naka-ku, Yokohama City, Kanagawa Prefecture, Japan.
  • Furuki T; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1 Fujimicho naka-ku, Yokohama City, Kanagawa Prefecture, Japan.
  • Sato K; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1 Fujimicho naka-ku, Yokohama City, Kanagawa Prefecture, Japan.
  • Terauchi Y; Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, 3-1 Fujimicho naka-ku, Yokohama City, Kanagawa Prefecture, Japan.
  • Tamura K; Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kanamori A; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Sci Rep ; 12(1): 16106, 2022 09 27.
Article em En | MEDLINE | ID: mdl-36167964
The cardiovascular and renal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1Ras) are enhanced by low/controlled blood pressure (BP). However, the BP-lowering efficacy of SGLT-2is and GLP-1Ras have not been compared directly. We compared the rates of achieving target BP with SGLT-2i and GLP-1Ra treatments in Japanese patients with type 2 diabetes mellitus (T2DM). This retrospective study included 384 SGLT-2i- and 160 GLP-1Ra-treated patients with BP > 130/80 mmHg before treatment. Inverse probability weighting methods using propensity scores were used in this study. The integrated odds ratios (OR) for BP control rates were calculated and clinical changes were analyzed using a generalized linear model. SGLT-2i treatment resulted in significantly higher BP control rates than that in the GLP-1Ra treatment (integrated OR = 2.09 [1.80, 2.43]). Compared with GLP-1Ra, SGLT-2i treatment demonstrated significantly larger decreases in diastolic BP, mean arterial pressure, and body weight (- 3.8 mmHg, P = 0.006; - 4.1 mmHg, P = 0.01; and - 1.5 kg, P = 0.008, respectively) and increased annual estimated glomerular filtration rate (eGFR; 1.5 mL/min/1.73 m2/year, P = 0.04). In T2DM patients with poorly controlled BP, compared with GLP-1Ra, SGLT-2i treatment significantly improved BP management and increased eGFR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido